Journal of Pain and Symptom Management
Volume 36, Issue 1 , Pages 54-68 , July 2008

Reliability, Validity, and Responsiveness of the Daily Sleep Interference Scale Among Diabetic Peripheral Neuropathy and Postherpetic Neuralgia Patients

  • Margaret K. Vernon, PhD

      Affiliations

    • United BioSource Corporation, Center for Health Outcomes Research, Bethesda, Maryland
    • Corresponding Author InformationAddress correspondence to: Margaret K. Vernon, PhD, United BioSource Corporation, Center for Health Outcomes Research, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD 20814, USA.
    • ,
  • Nancy A. Brandenburg, PhD

      Affiliations

    • Pfizer, Inc., New York, New York, USA
    • ,
  • Jose Ma. J. Alvir, DrPH

      Affiliations

    • Pfizer, Inc., New York, New York, USA
    • ,
  • Teresa Griesing, PhD

      Affiliations

    • Pfizer, Inc., New York, New York, USA
    • ,
  • Dennis A. Revicki, PhD

      Affiliations

    • United BioSource Corporation, Center for Health Outcomes Research, Bethesda, Maryland

,Accepted 11 September 2007.

  • Image Result

    Weekly mean DSIS for DPN and PHN patient groups over time.

    Weekly mean DSIS for DPN and PHN patient groups over time.

  • Image Result

    Mean weekly Sleep Interference Score by MOS-SS Sleep Disturbance Score groups in diabetes and postherpetic patients at baseline. DPN: F=78.45; P<0.001; PHN: F=109.59; P<0.001.

    Mean weekly Sleep Interference Score by MOS-SS Sleep Disturbance Score groups in diabetes and postherpetic patients at baseline. DPN: F=78.45; P<0.001; PHN: F=109.59; P<0.001.

  • Image Result

    Mean weekly Sleep Interference Score by MPQ-SF VAS Score in diabetes and postherpetic patients at Week 1. DPN: F=190.15; P<0.001; PHN: F=92.07; P<0.001. Scheffe post hoc tests showed that all gr

    Mean weekly Sleep Interference Score by MPQ-SF VAS Score in diabetes and postherpetic patients at Week 1. DPN: F=190.15; P<0.001; PHN: F=92.07; P<0.001. Scheffe post hoc tests showed that all groups were significantly different at the P<0.001 level.

  • Image Result
    Mean change in weekly Sleep Interference Score by PGIC Scores from baseline to end of treatment (Week 12) in diabetes patients. F=29.11; P<0.001.

    Mean change in weekly Sleep Interference Score by PGIC Scores from baseline to end of treatment (Week 12) in diabetes patients. F=29.11; P<0.001.

  • Image Result
    Mean change in weekly Sleep Interference Scores by PGIC Scores from baseline to end of treatment (Week 8) in postherpetic patients. F=31.17; P<0.001.

    Mean change in weekly Sleep Interference Scores by PGIC Scores from baseline to end of treatment (Week 8) in postherpetic patients. F=31.17; P<0.001.

 This study was supported by funding from Pfizer, Inc.

PII: S0885-3924(08)00142-5

doi: 10.1016/j.jpainsymman.2007.09.016

Journal of Pain and Symptom Management
Volume 36, Issue 1 , Pages 54-68 , July 2008

Article Tools

* Image Usage & Resolution